

November 2024

one  
nucleus™

ON eNews



## Welcome to this month's eNews



Tony Jones, CEO,  
One Nucleus

### Partnering, Policies and Parties

Although the clocks have gone back this month, I am delighted to see the same has not apparently been seen by the sector. Not there in person this year, but great to see colleagues Alicia Gailliez and Monalisa Breazu were all set to welcome visitors to the booth and joined by our collaborators Mike Ward (Clarivate) and Dennis Ford (LSN) among other wise owls.



Judging by the updates on social media, it is clear to see from here that there will be plenty to discuss and partner around at [Genesis](#) next month, where Mike will be presenting his now famous 'Winners & Losers 2024' keynote and Dennis will bring [RESI-London](#), the newest collaboration as Genesis evolves.

It now seems some time since the UK public elected the new Labour government, full of promise and anticipation as they took up post and have subsequently consulted and developed their thinking around how they can enable the Life Sciences sector to drive the UK's economic growth within their '[Invest 2035: a modern UK industrial strategy](#)'. This was quickly followed by the [Autumn Budget 2024](#). Not all negative for Science & Innovation support but not all positive for business either, so I am pleased to share thoughts below on where that may leave our home region. It's not just the UK that is watching the political landscape, of course. As I write, voting to choose the next President of the United States of America is hurtling towards its climax. It seems a little bit of a mixed bag across key US policy areas such as the Inflation Reduction Act, FDA governance, taxation, and Medicare, so again, our sector waits patiently to see the impact.

The political parties in power and how the global political landscape is anticipated to evolve will no doubt form parts of the keynote and networking discussions at Genesis as we debate what the Life Science sector might expect from capital markets, regulators, innovators, and our businesses. The timing of Genesis, with London's Oxford Street decked out for the festive season and the holidays approaching, creates a unique forum that enables our ecosystem to gather, consider what they have on their wish list from Bio-Santa, and seek out the Bio-Elves and partners who may help make their wishes come true. Whether everyone will be in

the mood to celebrate come the end of the year, I suspect will be determined by the above outcomes from bio-partnering, the achievements of those claiming to influence policies, and which political parties hold the aces for 2025.

### Keeping You in the Know?

I am delighted the items in this month's update include updates on Genesis and the associated events, updates about the One Nucleus reach and goals, some key insights from members and where our members are located, why and what we deliver for our members, and some key insights from members, Appleyard Lees and PharmaVentures, respectively.

To stay informed of all One Nucleus updates, disseminate your company's news, or track the announcements from other members, you can make full use of our [website](#), [LinkedIn](#), or [X](#) pages. The [news stream](#) contains numerous updates from our community. Enjoy the read (and check out the new [One Nucleus website!](#))

**Tony Jones, CEO, One Nucleus**

### Genesis Conference App Now Open! Start Your Networking Here...



Genesis is fast approaching and we have now launched the Genesis app, your gateway to partnering prior to the conference.

Taking place at 1 Wimpole Street on 4 December, Genesis is a hive of knowledge sharing and business development for the life science industry. Don't miss your change to participate - [register for Genesis here](#) and start networking early.



.....

### New Government Delivers Optimism and Concern for the Region's Life Sciences

Recent weeks have been filled with varying degrees of anticipation and apprehension with regards to what UK Government would start crystallising from grand election campaign gestures to actual measures and policies. Tony Jones explores the latest outcomes; 'Invest 2025: the UK's modern industrial strategy' and 'Autumn Budget 2024.' [Read the article here.](#)

### CRISPR – A Twist in the Tale in the Ongoing Patent Battle in Europe

CRISPR mediated gene editing technology is undoubtedly one of the biggest breakthroughs in biotech in recent years. As a result, not only have many patent applications been filed – and subsequently granted – to the underlying technology,

but they have also been the subject of a series of high-profile ownership disputes. Appleyard Lees investigates the pitfalls. [Read more here.](#)

### European Rare Disease M&A Activity in 2024

This white paper by PharmaVentures explores the key factors driving M&A activity in the European rare disease space and highlights notable deals and potential acquisition targets in 2024. [Read the white paper here.](#)

### The Power of Belonging

The regular opportunities to gather our community to share ideas and collaboratively problem-solve shared challenges enables important, trusted relationships and a sense of belonging to be built. Alicia Gailliez, Business Development Manager, One Nucleus examines your routes to success within our network. [Read the article.](#)

### What Happened at ON Helix 2024?

Whether or not you attended ON Helix 2024, our Cambridge conference focussing on key bio innovation trends, from developments in life science and technology research to their translation, you may find the [ON Helix Review](#) a useful reference tool.

### Visualising One Nucleus Members Around the World – A New Perspective!

At One Nucleus, international connectivity is more than just a concept; it is at the core of what our members do and hence why we seek to complement that connectivity in our member support. Monalisa Breazu, Learning & Development Administrator, One Nucleus provides [a new perspective on our international reach.](#)



One Nucleus Events

Training Courses

Industry News

Corporate Patron



Corporate Sponsors



Copyright © 2024

To contact us please email [info@onenucleus.com](mailto:info@onenucleus.com) or telephone: +44 (0)1223 896 450